MedTrace Logo

Pharmacokinetics of FDL169 in Healthy Female Subjects

NCT02680418 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2016-03-31

No results posted yet for this study

Summary

To determine the pharmacokinetics of single and multiple doses of FDL169 in healthy female subjects.

Conditions

Interventions

DRUG

FDL169

Sponsors & Collaborators

  • Flatley Discovery Lab LLC

    lead OTHER

Principal Investigators

  • Khalid Abou-Farha, MBChB MD PhD · Simbec Research

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2016-02-29
Completion
2016-02-29

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02680418 on ClinicalTrials.gov